S1P receptor modulating compounds and use thereof

1. A compound having the formula

and pharmaceutically acceptable salts thereof,

wherein

pheny ring A is optionally substituted with one, two or three substituents selected from the group consisting of halogen, hydroxyl, SR 2 , S(O) 2 R 2 , S(O) 2 NR 2 , NHS(O) 2 R 2 , COR 2 , CO 2 R 2 , cyano, amino, C 1-5 alkylamino, arylamino, heteroarylamino, C 1-6 alkyl, C 1-5 alkylthio, C 1-5 alkoxy, halogen-substituted C 1-6 alkyl, and halogen-substituted C 1-5 alkoxy;

R 2 is selected from the group consisting of hydrogen, hydroxyl, amino, C 1-5 alkylamino, arylamino, C 1-6 alkyl, C 1-5 alkoxy, C 1-5 alkylthio, halogen-substituted C 1-6 alkyl, halogen-substituted C 1-5 alkoxy, aryl, and heteroaryl;

the benzofuran ring is optionally substituted with 1 to 5 substituents selected from the group consisting of C 1-6 alkyl, C 1-5 alkylthio, C 1-5 alkoxy, halogen, hydroxyl, cyano, halogen-substituted C 1-6 alkyl and halogen-substituted C 1-5 alkoxy;

X is selected from the group consisting of WC(O)OR 6a , WP(O)R 6b R 6c , WS(O) 2 OH, WCONHSO 3 H and 1H-tetrazol-5-yl;

W is a direct bond, oxygen or C 1-4 alkyl having one or more substituents independently selected from the group consisting of halogen, hydroxyl, cyano, amino, alkylamino, arylamino, heteroarylamino groups, C 1-4 alkoxy and CO 2 H;

R 6a is hydrogen or C 1-4 alkyl;

R 6b and R 6c are independently hydrogen, hydroxyl, C 1-4 alkyl or halogen substituted C 1-4 alkyl;

Y is formula (a) where the left and right asterisks indicate the point of attachment

wherein

Q is selected from the group consisting of a direct bond, C═O, C═S, SO 2 , and (CR 10 R 11 ) m ;

m is 0, 1, 2 or 3;

R 7 and R 8 are joined together with the atoms to which they are attached to form a 4 to 7-membered ring, optionally having a heteroatom;

R 9 is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C 1-6 alkyl, C 1-5 alkylthio, C 1-5 alkoxy, halogen-substituted C 1-6 alkyl and halogen-substituted C 1-5 alkoxy;

R 10 and R 11 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C 1-6 alkyl, C 1-5 alkoxy, C 1-5 alkylthio, halogen-substituted C 1-6 alkyl and halogen-substituted C 1-5 alkoxy;

Z 1 and Z 2 are independently selected from the group consisting of O, NR 3 , S, S(O), S(O) 2 NR 3 , (CR 4 R 5 ) n , C═O, C═S, C═N-R 3 , and a direct bond, where R 3 is selected from the group consisting of hydrogen, hydroxyl, C 1-6 alkyl, C 1-5 alkoxy, C 1-5 alkylthio, halogen-substituted C 1-6 alkyl and halogen-substituted C 1-5 alkoxy, aryl, and heteroaryl, or when Z 2 is a direct bond, R 3 is a C 3 -C 6 ring optionally containing a heteroatom;

R 4 and R 5 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C 1-6 alkyl, C 1-5 alkoxy, C 1-5 alkylthio, halogen-substituted C 1-6 alkyl and halogen-substituted C 1-5 alkoxy, aryl, and heteroaryl or together with the carbon atom to which they are attached form C═O;

n is 0, 1, 2 or 3; and

R 1 is selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 1-5 alkoxy, C 1-5 alkylamino, aryl, and heteroaryl wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 1-5 alkoxy, C 1-5 alkylamino, aryl, and heteroaryl groups are optionally substituted with a substituent selected from the group consisting of hydroxyl, halogen, cyano, amino, alkylamino, aryl amino, and heteroarylamino and wherein the aryl and heteroaryl groups are optionally substituted with 1 to 5 substituents selected from the group consisting of hydroxyl, halogen, cyano, C 1-6 alkyl, C 1-5 alkylthio, C 1-5 alkoxy, and C 3-6 cycloalkyl.

2. The compound of claim 1 , wherein Z 1 and Z 2 are independently selected from the group consisting of O, (CR 4 R 5 ) n , and a direct bond.

3. The compound of claim 2 , wherein R 4 and R 5 are hydrogen.

4. The compound of claim 1 , wherein R 1 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, C 1-5 alkoxy, aryl and heteroaryl.

5. The compound of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, maleate, citrate, fumarate, succinate, tartarate, mesylate, sodium, potassium, magnesium, and calcium salts.

6. A compound having the formula

wherein

the benzofuran ring is optionally substituted with 1 to 5 substituents selected from the group consisting of C 1-6 alkyl, C 1-5 alkylthio, C 1-5 alkoxy, halogen, hydroxyl, cyano, halogen-substituted C 1-6 alkyl and halogen-substituted C 1-5 alkoxy;

pheny ring A is optionally substituted with one, two or three substituents selected from the group consisting of halogen, hydroxyl, SR 2 , S(O) 2 R 2 , S(O) 2 NR 2 , NHS(O) 2 R 2 , COR 2 , CO 2 R 2 , cyano, amino, C 1-5 alkylamino, arylamino, heteroarylamino, C 1-6 alkyl, C 1-5 alkylthio, C 1-5 alkoxy, halogen-substituted C 1-6 alkyl, and halogen-substituted C 1-5 alkoxy;

R 2 is selected from the group consisting of hydrogen, hydroxyl, amino, C 1-5 alkylamino, arylamino, C 1-6 alkyl, C 1-5 alkoxy, C 1-5 alkylthio, halogen-substituted C 1-6 alkyl, halogen-substituted C 1-5 alkoxy, aryl and heteroaryl;

X is -C(O)OR 6a , where R 6a is hydrogen or C 1-4 alkyl;

Y is formula (a)

wherein

Q is (CR 10 R 11 ) m ;

m is 0, 1, 2, 3 or 4;

R 7 and R 8 taken with the atoms to which they are attached, form a 4 to 7-membered ring, optionally having a heteroatom;

R 9 is selected from the group consisting of hydrogen, halogen, hydroxyl, and cyano;

Z 1 and Z 2 are independently O or (CR 4 R 5 ) n , where R 4 and R 5 are independently hydrogen, halogen, hydroxyl, cyano, C 1-6 alkyl, or C 1-5 alkoxy;

n is 0, 1, 2 or 3; and

R 1 is selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 1-5 alkoxy, C 1-5 alkylamino, aryl, and heteroaryl wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 1-5 alkoxy, and C 1-5 alkylamino groups are optionally substituted with a substituent selected from the group consisting of hydroxyl, halogen, cyano, amino, alkylamino, arylamino, and heteroarylamino and wherein the aryl and heteroaryl groups are optionally substituted with one to five substituents selected from the group consisting of hydroxyl, halogen, cyano, C 1-6 alkyl, C 1-5 alkylthio, C 1-5 alkoxy, and C 3-6 cycloalkyl or a pharmaceutically acceptable salt thereof.

7. The compound of claim 6 , wherein R 1 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, C 1-5 alkoxy, aryl, and heteroaryl.

8. The compound of claim 6 , wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, maleate, citrate, fumarate, succinate, tartarate, mesylate, sodium, potassium, magnesium, and calcium salts.

9. A pharmaceutical composition comprising the compound of claim 1 in a therapeutically effective amount.

10. A compound selected from the group consisting of

1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acid;

1-((4-(5-Butylbenzofuran-2-yl)phenyl)methyl)azetidine-3-carboxylic acid;

1-(4-(5-Butoxybenzofuran-2-yl)phenyl)methyl)azetidine-3-carboxylic acid;

1-((4-(5-Benzylbenzofuran-2-yl)phenyl)methyl)azetidine-3-carboxylic acid;

1-((4-(7-Benzylbenzofuran-2-yl)phenyl)methyl)azetidine-3-carboxylic acid;

1-(4-(5-cyclohexylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acid;

1-(4-(5-cyclohexylbenzofuran-2-yl)benzyl)piperidine-4-carboxylic acid;

1-((4-(5-Butylbenzofuran-2-yl)phenyl)methyl)piperidine-4-carboxylic acid;

1-((4-(5-Benzylbenzofuran-2-yl)phenyl)methyl)piperidine-4-carboxylic acid;

1-((4-(5-isobutylbenzofuran-2-yl)phenyl)methyl)azetidine-3-carboxylic acid;

1-((4-(5-phenethylbenzofuran-2-yl)phenyl)methyl)azetidine-3-carboxylic acid;

1-(4-(5-(pyridin-3-yl)benzofuran-2-yl)benzyl)azetidine-3-carboxylic acid;

1-(4-(5-isobutylbenzofuran-2-yl)benzyl)piperidine-4-carboxylic acid;

1-((4-(5-Benzylbenzofuran-2-yl)2-fluorophenyl)methyl)azetidine-3-carboxylic acid;

1-((4-(5-Benzylbenzofuran-2-yl)-3-fluorophenyl)methyl)azetidine-3-carboxylic acid;

1-(4-(5-Butoxybenzofuran-2-yl)phenyl)methyl)piperidine-4-carboxylic acid;

1-(4-(5-(6-methylpyridin-2-yl)benzofuran-2-yl)benzyl)azetidine-3-carboxylic acid;

1-(4-(5-phenoxybenzofuran-2-yl)benzyl)azetidine-3-carboxylic acid;

1-((4-(5-Isopentylbenzofuran-2-yl)phenyl)methyl)azetidine-3-carboxylic acid;

1-((4-(6-Butoxybenzofuran-2-yl)phenyl)methyl)azetidine-3-carboxylic acid;

1-((4-(5-Butoxybenzofuran-2-yl)3-fluorophenyl)methyl)azetidine-3-carboxylic acid;

1-((4-(5-Butoxybenzofuran-2-yl)-3-methoxyphenyl)methyl)azetidine-3-carboxylic acid;

1-((4-(5-cyclohexylbenzofuran-2-yl)3-fluorophenyl)methy)azetidine-3-carboxylic acid;

1-((4-(5-(thiophen-2-yl)benzofuran-2-yl)phenyl)methyl)azetidine-3-carboxylic acid;

1-(4-(5-cyclopentylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acid;

1-(3-fluoro-4-(5-(piperidin-l-yl)benzofuran-2-yl)benzyl)azetidine-3-carboxylic acid trifluoroacetic acid salt;

1-((4-(5-benzylbenzofuran-2-yl)-3-methoxyphenyl)methyl)azetidine-3-carboxylic acid;

1-(4-(5-benzylbenzofuran-2-yl)-3-chlorobenzyl)azetidine-3-carboxylic acid;

1-(4-(5-(cyclopentylmethoxy)benzofuran-2-yl)-3-fluorobenzyl)azetidine-3- carboxylic acid;

1-(4-(5-(cyclopentylmethoxy)benzofuran-2-yl)benzyl)azetidine-3-carboxylic acid;

1-(4-(5-benzylbenzofuran-2-yl)-3-cyanobenzyl)azetidine-3-carboxylic acid;

1-(4-(5-benzylbenzofuran-2-yl)-3-fluorobenzyl)pyrrolidine-3-carboxylic acid;

1-(4-(5-cyclopentylbenzofuran-2-yl)-3-fluorobenzyl)azetidine-3-carboxylic acid;

1-(4-(5-benzylbenzofuran-2-yl)-3-methylbenzyl)azetidine-3-carboxylic acid;

1-(4-(5-cyclopentylbenzofuran-2-yl)-3-methoxybenzyl)azetidine-3-carboxylic acid;

1-(4-(5-benzylbenzofuran-2-yl)-3,5-difluorobenzyl)azetidine-3-carboxylic acid;

1-(4-(5-(cyclopropylmethoxy)benzofuran-2-yl)-3-fluorobenzyl)azetidine-3-carboxylic acid;

1-(4-(5-butoxybenzofuran-2-yl)-3-chlorobenzyl)azetidine-3-carboxylic acid;

1-(3-chloro-4-(5-cyclopentylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acid;

4-(4-(5-benzylbenzofuran-2-yl)-3-fluorobenzyl)morpholine-2-carboxylic acid;

4-(4-(5-(cyclopentylmethoxy)benzofuran-2-yl)-3-fluorobenzyl)morpholine-2-carboxylic acid; and

1-(3-fluoro-4-(5-(1-(methylsulfonyl)piperidin-4-yl)benzofuran-2-yl)benzyl)azetidine-3-carboxylic acid;

or pharmaceutically acceptable salts thereof.

11. The compound of claim 1 wherein

R 1 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl wherein the aryl is phenyl, wherein the heteroaryl is pyridinyl, methylpyridinyl, or thiophenyl;

Z 1 and Z 2 are independently selected from the group consisting of a direct bond, O, and (CR 4 R 5 ) n ;

R 4 and R 5 are hydrogen;

n is 1 or 2;

phenyl ring A is optionally substituted with 1 or 2 substituents selected from the group consisting of C 1-5 alkoxy, C 1-6 alkyl, cyano, and halogen;

Q is (CR 10 R 11 ) m ;

m is 1;

R 7 and R 8 taken with the atoms to which they are attached form a ring; wherein the ring is selected from the group consisting of azetidine, piperidine, pyrrolidine, and morpholine;

R 9 is hydrogen;

R 10 and R 11 are independently selected from the group consisting of hydrogen and C 1-6 alkyl.